SC
RYTM icon

SummitTX Capital’s Rhythm Pharmaceuticals RYTM Stock Holding History

SummitTX Capital’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14M Sell
126,401
-39,198
-24% -$3.54M 0.36% 56
2026
Q1 		$14.4M Buy
165,599
+84,870
+105% +$8.25M 0.45% 35
2025
Q4 		$8.64M Buy
80,729
+68,860
+580% +$7.3M 0.26% 89
2025
Q3 		$1.2M Sell
11,869
-13,583
-53% -$1.26M 0.05% 349
2025
Q2 		$1.61M Buy
25,452
+8,109
+47% +$497K 0.07% 286
2025
Q1 		$919K Buy
+17,343
New +$962K 0.04% 422

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

SummitTX Capital's RYTM Position: Q2 2026 in Review

SummitTX Capital reduced its Rhythm Pharmaceuticals (RYTM) stake by 24% in Q2 2026, selling an estimated $3.54M and leaving 126,401 shares worth $14M. The position accounts for 0.36% of the portfolio, ranked #56.

SummitTX Capital first reported a position in RYTM in Q1 2025 and has held it in 6 quarters since. The position peaked at $14.4M in Q1 2026. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • SummitTX Capital held 126,401 shares of Rhythm Pharmaceuticals worth $14M as of Q2 2026.
  • SummitTX Capital sold 39,198 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $3.54M.
  • Rhythm Pharmaceuticals made up 0.36% of SummitTX Capital's portfolio in Q2 2026, its #56 holding.
  • SummitTX Capital first reported a position in Rhythm Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • SummitTX Capital's Rhythm Pharmaceuticals position peaked at $14.4M in Q1 2026.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.